320 related items for PubMed ID: 20551193
1. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D.
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[Abstract] [Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
3. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
4. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.
J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
[Abstract] [Full Text] [Related]
5. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K.
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[Abstract] [Full Text] [Related]
6. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I.
Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
[Abstract] [Full Text] [Related]
7. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[Abstract] [Full Text] [Related]
8. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
9. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[Abstract] [Full Text] [Related]
10. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[Abstract] [Full Text] [Related]
11. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M.
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[Abstract] [Full Text] [Related]
12. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[Abstract] [Full Text] [Related]
13. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD.
Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
[Abstract] [Full Text] [Related]
14. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT.
J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
[Abstract] [Full Text] [Related]
15. Immunoglobulin failure and retreatment in Kawasaki disease.
Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
Pediatr Cardiol; 2003 Apr; 24(2):145-8. PubMed ID: 12457253
[Abstract] [Full Text] [Related]
16. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[Abstract] [Full Text] [Related]
17. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
Clin Drug Investig; 2011 Oct; 31(3):191-9. PubMed ID: 21456105
[Abstract] [Full Text] [Related]
18. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
19. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[Abstract] [Full Text] [Related]
20. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
